Roivant Sciences Insider Sold Shares Worth $7,262,000
Eric Venker, President of Roivant Sciences and CEO of Immunovant, sold 200,000 shares of Roivant common stock in a transaction reported via SEC filing.
Stocks · News reference
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Enact Holdings Q3 2026 Earnings Call Transcript
Enact Holdings (NASDAQ:ACT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
Aduro Clean Technologies Completes Longest NGP Pilot Plant Campaign
Aduro Clean Technologies has successfully completed a 120-hour pilot plant campaign, marking its longest continuous operation to date using post-consumer plastic waste.
Phillips 66 Appoints Chris Chandler as Executive Vice President and Strategic Advisor to the CEO
Phillips 66 has appointed Chris Chandler as Executive Vice President and Strategic Advisor to the CEO, leveraging his extensive experience in the energy industry.
Enact Holdings, Inc. Reports Third Quarter 2026 Financial Results
Enact Holdings, Inc. announced its financial results for the third quarter of 2026, reporting GAAP net income of $159 million and declaring a quarterly dividend of $0.24 per share.
H.C. Wainwright Assumes Coverage of Insmed with Buy Rating
Analyst firm H.C. Wainwright & Co. has initiated coverage of Insmed with a Buy rating and a price target of $220.